A. Eggermont presented the results of the EORTC study for Stage III Melanoma- Ipi 10 mg/kg (induction plus maintenance) versus placebo in about 1000 patients with nearly fully-resected Melanoma in a high-risk patient population for relapse.
Results:
relapses in 234/ 475 with Ipi versus 294/ 476 with placebo, after a median 26.1 versus 17.1 months respectively.
Especially profiting appear patients in stage 3b and 3c and the ones with ulcerated tumours, while the data is too immature for 3a patients who might or might not profit.
Side effects were comparable to the ones known for Stage IV Melanoma, so this is unfortunately not a treatment without problems.
| Pbo | Ipi | |
|---|---|---|
| No. RFS events | 294 | 234 |
| 3-Year rates (SE) | 34.8% (2.4%) | 46.5% (2.5%) |
| Median (mos) | 17.1 | 26.1 |
| HR (95% CI) | 0.75 (0.64–0.90) | |
| Log-rank | P = 0.0013 | |
http://abstracts.asco.org/144/AbstView_144_130118.html
LBA9008
No comments:
Post a Comment